Publication Date
11-1-2025
Journal
European Journal of Heart Failure
DOI
10.1002/ejhf.3683
PMID
40425519
PMCID
PMC12765049
PubMedCentral® Posted Date
5-27-2025
PubMedCentral® Full Text Version
Post-print
Abstract
The high disease burden and bidirectional relationship of chronic kidney disease (CKD), heart failure (HF) and other cardiovascular disease (CVD) necessitate the need for early diagnosis of these diseases. While current screening and detection methods are recommended by CKD and CVD guidelines, their adoption in practice is low. Urine albumin-to-creatinine ratio (uACR) is recognized as a diagnostic marker for CKD and a prognostic marker for CKD progression, HF and CVD outcomes, therefore albuminuria changes have been accepted as a surrogate outcome for kidney and cardiovascular endpoints. Furthermore, clinical trials investigating guideline-directed medical therapies have shown that uACR reductions are accompanied by risk reductions for cardiovascular, HF and other CKD outcomes. However, uACR is not routinely measured in patients at risk of kidney and heart disease, and its utility for detection, risk stratification and prediction models may not be fully appreciated in routine clinical practice. This review will discuss the effectiveness and implications of uACR screening as a method for heart and kidney disease diagnosis and risk assessment.
Keywords
Humans, Albuminuria, Heart Failure, Biomarkers, Renal Insufficiency, Chronic, Creatinine, Risk Assessment, Cardiovascular Diseases, Prognosis, Cardiovascular disease, Chronic kidney disease, Detection, Diagnosis, Heart failure, Risk assessment, Screening, Urine albumin‐to‐creatinine ratio
Published Open-Access
yes
Recommended Citation
Biykem Bozkurt, Patrick Rossignol, and Joseph A Vassalotti, "Albuminuria as a Diagnostic Criterion and a Therapeutic Target in Heart Failure and Other Cardiovascular Disease" (2025). Faculty, Staff and Students Publications. 6644.
https://digitalcommons.library.tmc.edu/baylor_docs/6644